Urinary miRNA in Endometrial Cancer Study
Overview
This study is a prospective feasibility study with the addition of a retrospective cohort study on the the expression of microRNA in urine in endometrial cancer patients.
Full Title of Study: “Urinary microRNA Expression in Endometrial Cancer Patients – a Feasibility Study”
Study Type
- Study Type: Observational
- Study Design
- Time Perspective: Prospective
- Study Primary Completion Date: March 26, 2020
Interventions
- Diagnostic Test: Urinary miRNA
- MiRNA detection in urine
Arms, Groups and Cohorts
- Endometrial cancer patients
- Control group
- Patients without cancer
Clinical Trial Outcome Measures
Primary Measures
- Accuracy of predictive value of miRNA test in detecting endometrial cancer
- Time Frame: 6 months
- To determine if miRNA can distinguish endometrial cancer patients from healthy patients
Secondary Measures
- Correlation to final histology
- Time Frame: 6 months
- To determine how well miRNA correlates with final histology, i.e. can miRNA determine the subtype of endometrial cancer
Participating in This Clinical Trial
Inclusion Criteria
- Confirmed diagnosis of endometrial cancer – Age: 18 years or older Exclusion Criteria:
- Prior or coexisting other malignancies – Autoimmune disorders (other than diabetes mellitus)
Gender Eligibility: Female
Minimum Age: 18 Years
Maximum Age: N/A
Are Healthy Volunteers Accepted: Accepts Healthy Volunteers
Investigator Details
- Lead Sponsor
- Royal Cornwall Hospitals Trust
- Provider of Information About this Clinical Study
- Sponsor
Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.